Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | FER | P16591 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18925458 | 0.83 | JAK3 (0.42) | HCRTR1TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL10251395 | 0.83 | JAK3 (0.42) | HCRTR1TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL4368419 | 0.79 | FER (0.36) | CHEK1RPS6KA3SRPK1ARTAS1R3 | |
| SCHEMBL14976854 | 0.78 | SYK (0.39) | FGFR4HCRTR1DGAT1KCNH2FER | |
| SCHEMBL9102105 | 0.77 | GPR65 (0.40) | FGFR4HCRTR1DGAT1KCNH2AR | |
| SCHEMBL2716165 | 0.77 | GPR65 (0.40) | FGFR4HCRTR1DGAT1KCNH2AR | |
| SCHEMBL16465498 | 0.76 | PRKCQ (0.43) | FGFR4F2RHCAR3 | |
| SCHEMBL16671742 | 0.76 | FGFR4 (0.47) | FGFR4CHEK1RPS6KA3SRPK1AR | |
| SCHEMBL496194 | 0.76 | CHEK1 (0.40) | CHEK1RPS6KA3SRPK1ARTAS1R3 | |
| SCHEMBL14956530 | 0.76 | JAK3 (0.46) | HCRTR1DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763975-B1 | 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2016-04-06 | — | — | EP | disclosed |
| US-8987456-B2 | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140303206-A1 | 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | MERCK SHARP & DOHME LLC | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303206-A1 | 3-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors | SYK, BTK, LCK | FGFR4 864/4885HCRTR1 3500/4885DGAT1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.